Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Fusion Antibodies's 3-Year ROIIC % for the quarter that ended in Mar. 2025 was 29.91%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Fusion Antibodies's 3-Year ROIIC % or its related term are showing as below:
LSE:FAB's 3-Year ROIIC % is ranked better than 68.38% of 1322
companies
in the Biotechnology industry
Industry Median: -4.835
vs LSE:FAB: 29.91
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Fusion Antibodies 3-Year ROIIC % Related Terms
Fusion Antibodies 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Fusion Antibodies's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:FAB vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Fusion Antibodies's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fusion Antibodies 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fusion Antibodies's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Fusion Antibodies's 3-Year ROIIC % falls into.
Fusion Antibodies's 3-Year ROIIC % for the quarter that ended in Mar. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -1.714956 (Mar. 2025) - -1.192765 (Mar. 2022) )
/
( 0.539 (Mar. 2025) - 2.285 (Mar. 2022) )
=
-0.522191
/
-1.746
=
29.91%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Fusion Antibodies (LSE:FAB) has a 3-Year ROIIC % of 29.91 as of Mar. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Fusion Antibodies and its competitors. According to the industry distribution chart, Fusion Antibodies ranks #418 out of 1322 companies in the Biotechnology industry, placing it in the top 31.6%.
Is Fusion Antibodies' 3-Year ROIIC % too high?
Fusion Antibodies' current 3-Year ROIIC % is 29.91. Based on the distribution chart, Fusion Antibodies ranks #418 out of 1322 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fusion Antibodies has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fusion Antibodies' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fusion Antibodies ranks #418 out of 1322 companies for 3-Year ROIIC %. This puts Fusion Antibodies in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Fusion Antibodies and its competitors. Fusion Antibodies's current 3-Year ROIIC % is 29.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.10 — trading 157.5% above its estimated fair value. The current 3-Year ROIIC % is 29.91. Fusion Antibodies' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current 3-Year ROIIC % is 29.91 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fusion Antibodies (LSE:FAB) Overvalued in 2026?
Based on GuruFocus' analysis, Fusion Antibodies stock appears to be overvalued.
The current stock price of £0.10 is trading 157.5% above its estimated GF Value™ of £0.04.
GuruFocus considers Fusion Antibodies to be Significantly Overvalued.
Key valuation signals for LSE:FAB:
3-Year ROIIC %: 29.91
GF Value™: £0.04 vs. price of £0.10 (157.5% above fair value)
No single metric tells the full story. See the LSE:FAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
32GF Score
Get the complete analysis for LSE:FAB
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FAB has been successfully added to your 
